Showing 10,141 - 10,160 results of 10,354 for search '(( significant processes decrease ) OR ( significant ((mean decrease) OR (we decrease)) ))', query time: 0.63s Refine Results
  1. 10141

    Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  2. 10142

    Data Sheet 1_Adherence to a “MediterrAsian” diet is associated with weight loss-independent improvements in liver fat and lipid profile, but not glucoregulation or inflammation: se... by Yu Chung Chooi (18968382)

    Published 2025
    “…</p>Results<p>Body weight, total body fat, visceral and subcutaneous adipose tissues, and liver fat decreased significantly after the intervention, in tandem with improvements in markers of glucose and lipid metabolism and inflammation. …”
  3. 10143

    Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  4. 10144

    Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  5. 10145

    Supplementary Material for: Long-term outcomes and clinical factors associated with conventional therapy failure in intestinal Behçet’s disease: A retrospective cohort study in Jap... by figshare admin karger (2628495)

    Published 2025
    “…Concomitant glucocorticoid use significantly decreased from 12.7±11.7 mg/day at baseline to 2.4±2.5 mg/day at 1 year (p<0.001). …”
  6. 10146

    Table 1_HIV risk and influence factors among MSM who had sought sexual partners in core venues: a continuous sentinel surveillance in 2010–2022.doc by Zijie Yang (6330086)

    Published 2024
    “…MSM sexual contact network and venue network were acquired, and network metrics were employed to identify core MSM and core venues. We compared the risk of HIV and risk behaviors between MSM who sought sexual partners in core venues and those who did not, with subgroup analyses based on different time periods.…”
  7. 10147

    Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  8. 10148

    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  9. 10149

    Image 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  10. 10150

    Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  11. 10151

    Table 1_Associations of specific food sources of dietary fat with prostate cancer incidence and mortality: results from a large prospective cohort.docx by Yong-xin Fu (22644743)

    Published 2025
    “…</p>Results<p>During follow-up, we documented 4,308 incident cases of PCa, of whom 392 died from PCa. …”
  12. 10152

    Image 1_HIV risk and influence factors among MSM who had sought sexual partners in core venues: a continuous sentinel surveillance in 2010–2022.png by Zijie Yang (6330086)

    Published 2024
    “…MSM sexual contact network and venue network were acquired, and network metrics were employed to identify core MSM and core venues. We compared the risk of HIV and risk behaviors between MSM who sought sexual partners in core venues and those who did not, with subgroup analyses based on different time periods.…”
  13. 10153

    Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  14. 10154

    Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  15. 10155

    Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  16. 10156

    Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”
  17. 10157
  18. 10158

    Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

    Published 2025
    “…This meta-analysis aims to compare the antitumor effectiveness and safety profiles of PIBC with PIC.</p>Methods<p>We systematically searched six databases to identify eligible RCTs. …”
  19. 10159

    Image 2_HIV risk and influence factors among MSM who had sought sexual partners in core venues: a continuous sentinel surveillance in 2010–2022.png by Zijie Yang (6330086)

    Published 2024
    “…MSM sexual contact network and venue network were acquired, and network metrics were employed to identify core MSM and core venues. We compared the risk of HIV and risk behaviors between MSM who sought sexual partners in core venues and those who did not, with subgroup analyses based on different time periods.…”
  20. 10160

    Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…However, with the increasing number of phase 3 randomized controlled trials (RCTs) published in recent years, it is essential to re-evaluate the validity of this conclusion and to comprehensively assess the efficacy and safety across diverse patient subgroups.</p>Methods<p>We systematically reviewed phase 3 RCTs comparing PC with chemotherapy alone for stage IIIb-IV NSCLC. …”